Skip to main content
. Author manuscript; available in PMC: 2012 Dec 6.
Published in final edited form as: J Neurosci. 2012 Jun 6;32(23):7806–7818. doi: 10.1523/JNEUROSCI.3243-11.2012

Figure 4. iNOS is not required for the proliferation of control and PTEN-deficient astrocytes.

Figure 4

(A) Population growth of MSCV;Stat3loxP/loxP and MSCV;Stat3−/− astrocytes was assessed as in Fig. 3C. Pharmacological inhibition of iNOS with 1400W had little or no effect on the population growth of MSCV;Stat3loxP/loxP and MSCV;Stat3−/− astrocytes compared to vehicle treatment (n = 3).

(B) Population growth of PTENi;Stat3loxP/loxP and PTENi;Stat3−/− astrocytes was assessed as in Fig. 3C. Pharmacological inhibition of iNOS with 1400W had little or no effect on the population growth of PTENi;Stat3loxP/loxP and PTENi;Stat3−/− astrocytes compared to vehicle treatment (n = 3).

(C) Population growth of MSCV;Stat3loxP/loxP and MSCV;Stat3−/− astrocytes was assessed as in Fig. 3C. The nitric oxide donor SNAP had little or no effect on the population growth of MSCV;Stat3loxP/loxP and MSCV;Stat3−/− astrocytes compared to vehicle treatment (n = 3).

(D) Population growth of primary mouse astrocytes was assessed as in Fig. 3C. Pharmacological inhibitors and activators of the iNOS pathway had little or no effect on the population growth of primary mouse astrocytes compared to vehicle treatment (n = 3).

(E) Primary mouse astrocytes treated with inhibitors and activators of the iNOS pathway were subjected to immunocytochemistry using the BrdU antibody. Inhibition or activation of the iNOS pathway had little or no effect on BrdU incorporation of primary mouse astrocytes compared to vehicle treatment. In control experiments, the nucleoside analog Arabinose C (AraC) substantially reduced BrdU incorporation in primary astrocytes compared to vehicle treatment. Scale bar = 20 μm.

(F) Primary mouse astrocytes analyzed as in (E) were quantified for the percentage of BrdU positive cells. Inhibition or activation of the iNOS pathway had little or no effect on BrdU incorporation in primary astrocytes. In control experiments, the nucleoside analog Arabinose C (AraC) significantly reduced BrdU incorporation compared to vehicle treatment (ANOVA, p < 0.0001, n = 3).